The Combating Illicit Xylazine Act would add xylazine to Schedule III of the Controlled Substances Act and create special rules for how it can be handled, prescribed, tracked, and reported. It would narrow who counts as an “ultimate user” of xylazine to certain veterinary and animal-control uses, while giving manufacturers, the FDA, and DEA a transition period to adjust. The bill also directs the Sentencing Commission to review penalties and requires the Attorney General, DEA, and FDA to report to Congress on illicit xylazine use within 18 months and again after 4 years. In practice, it mainly affects veterinarians, pharmacies, animal owners, manufacturers, law enforcement, and people involved in illicit drug trafficking or misuse.
What This Bill Does
- Adds xylazine to Schedule III of the Controlled Substances Act.
- Limits “ultimate user” possession to veterinarian-dispensed animal uses, government animal-control programs, and wildlife programs.
- Delays labeling, packaging, distribution-logistics rules for 1 year after enactment.
- Delays practitioner registration, inventory, and recordkeeping rules for 60 days after enactment.
- Requires DEA and FDA to help expedite manufacturer submissions tied to Schedule III placement.
Who This Bill Affects
For a typical person, this bill would not change day-to-day life directly, but it could affect the illicit drug supply if tighter federal controls make xylazine harder to divert and distribute. If you are a veterinarian, animal owner, pharmacy, manufacturer, or someone working in drug enforcement or public health, the bill would add new Schedule III rules, reporting, and transition requirements, with special exceptions for certain animal and wildlife uses.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Public-health officials and addiction-response advocates They would likely support tighter federal control because the bill targets diversion of xylazine into the illicit drug market and requires reports on prevalence, origin, and analogues. They may see Schedule III placement and ARCOS tracking as tools to better understand and interrupt supply chains.
- Law enforcement and prosecutors They would likely favor the bill because it clarifies federal penalties for xylazine-related offenses and directs the Sentencing Commission to align guidelines with the new scheduling. The reporting requirements could also help investigators identify trafficking patterns and sources.
- Veterinarians and animal-care users who need lawful access Supporters in this group may back the bill’s narrow access rules because it preserves legitimate animal use while creating clear boundaries against misuse. The delayed compliance dates give practices and pharmacies time to adjust.
- Veterinary clinics and animal pharmacies concerned about compliance burden They may argue that scheduling xylazine will add paperwork, inventory controls, and recordkeeping requirements for a drug that is medically necessary in animal care. Even with transition periods, new federal controls can raise administrative and operating costs.
- Manufacturers and distributors of veterinary drugs They may oppose added controlled-substance compliance requirements because it can disrupt supply chains and increase security and reporting obligations. The bill’s transition language helps, but it still ties xylazine production to a more restrictive federal regime.
- Harm-reduction advocates and some public-health researchers They may worry that tighter scheduling could make legitimate monitoring harder or push use further underground without fully solving the overdose problem. They may prefer more focus on treatment, outreach, and surveillance rather than mainly criminal-control tools.
Key Implications
-
““add at the end the following: ‘(f) ... any quantity of xylazine.’””
This places xylazine in Schedule III, which is the central federal change. That means the substance would be treated as a controlled drug under federal law rather than as an ordinary veterinary chemical.
-
““the term ‘ultimate user’ means ... for an animal owned by the person””
This narrows who can legally possess xylazine for animal-related use. It is designed to keep legitimate veterinary possession legal while limiting broader access.
-
““shall not take effect for xylazine until ... 1 year after””
The bill delays labeling, packaging, and distribution-logistics requirements for a year, giving businesses time to adapt to the new controlled-substance status.
-
““shall not take effect ... until ... 60 days after””
Practitioner registration, inventory, and recordkeeping rules would start sooner than the labeling rules but still include a short grace period. That reduces immediate disruption for veterinarians and other practitioners.
-
““submit to Congress a report ... not later than 18 months””
Congress would receive a federal report on the prevalence, diversion, origins, and possible analogues of illicit xylazine. This creates a formal information-gathering requirement and could support future legislation.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- HR 1266
- Congress
- 119th Congress
- Official title
- Combating Illicit Xylazine Act
- Policy area
- Healthcare
- Latest action
- Forwarded by Subcommittee to Full Committee by Voice Vote. (June 25, 2026)
- Last updated
- June 27, 2026
Latest Status
June 25, 2026
Forwarded by Subcommittee to Full Committee by Voice Vote.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.